The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...
A real-world analysis of more than 60,000 patients in the US finds median survival increased by almost 7 months from 2011 to ...
Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...
Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...
Investing.com -- Roche (SIX: ROG ) shares rose more than 6% on Tuesday after the Swiss drugmaker reported an unexpected interim success in its lidERA study of the breast cancer drug giredestrant.
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus ...
The company said the drug helped women with a form of early breast cancer live longer without the disease progressing, ...
Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...
Roche's giredestrant has experienced a notable turnaround after initial challenges in phase 2 trials. The company previously reported a phase 3 win for the drug in September, which was further ...
Shares in Swiss healthcare company Roche surged to an eight-month high on Tuesday after results from a clinical trial of its ...
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback